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Abstract
As the enhanced permeation and retention (EPR) effect continues to be a controversial topic in 
nanomedicine, we sought to examine EPR as a function of nanoparticle size, tumor model, and 
tumor location, while also evaluating tumors for EPR mediating factors such as microvessel 
density, vascular permeability, lymphatics, stromal content, and tumor-associated immune cells. 
Tumor accumulation was evaluated for 55 × 60, 80 × 180, and 80 × 320 nm PRINT particles in 
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four subcutaneous flank tumor models (SKOV3 human ovarian, 344SQ murine nonsmall cell lung, 
A549 human nonsmall cell lung, and A431 human epidermoid cancer). Each tumor model 
revealed specific particle accumulation trends with evident particle size dependence. Immuno-
histochemistry staining revealed differences in tumor microvessel densities that correlated with 
overall tumor accumulation. Immunofluorescence images displayed size-mediated tumor 
penetration with signal from the larger particles concentrated close to the blood vessels, while 
signal from the smaller particle was observed throughout the tissue. Differences were also 
observed for the 55 × 60 nm particle tumor penetration across flank tumor models as a function of 
stromal content. The 55 × 60 nm particles were further evaluated in three orthotopic, metastatic 
tumor models (344SQ, A549, and SKOV3), revealing preferential accumulation in primary tumors 
and metastases over healthy tissue. Moreover, we observed higher tumor accumulation in the 
orthotopic lung cancer models than in the flank lung cancer models, whereas tumor accumulation 
was constant for both orthotopic and flank ovarian cancer models, further demonstrating the 
variability in the EPR effect as a function of tumor model and location.
Graphical abstract
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Cancerous tissue undergoes rapid angiogenesis yielding poorly organized, nonuniform, and 
chaotic vasculature, producing irregular blood flow throughout the tumor mass. Leaky 
vasculature coupled with poor lymphatic drainage, allows for large macromolecules and 
nanoparticles to extravasate from the tumor vasculature and remain within the tumor mass.1 
This phenomenon, known as the enhanced permeability and retention (EPR) effect, is highly 
heterogeneous within and across tumor models and is dependent on the unique properties of 
the specific cancer: tumor type, location, and mass size.2–6 Simultaneously, these attributes 
lead to major differences in macromolecular and nanoparticle accumulation and penetration, 
putting up a potential barrier for clinical translation.
The degree of EPR, and thus nanoparticle tumor accumulation, can fluctuate drastically due 
to heterogeneity of intratumoral blood flow, vascular permeability, stromal content, 
presence/absence of a functional lymphatic network, and level of interstitial pressure.2,7–11 
Other mediating factors include tumor-associated immune cells and the mononuclear 
phagocyte system (MPS) activity, which fluctuate from cancer to cancer, affecting particle 
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circulation profiles, and tumor accumulation.3 It has also been noted that tumor-associated 
macrophages (TAMs) can influence particulate transport and drug release.12,13 Perhaps the 
most important factor influencing particle tumor accumulation is the pore size of the leaky 
tumor vasculature, which differs greatly within and across tumor models, making it difficult 
to define an optimal particle size/shape.14,15 In general, a consensus in literature exists that 
decreasing carrier size (while staying above the limit for renal clearance) will improve tumor 
deposition.11,16–19
While reducing particle size is generally considered advantageous, tumor deposition and 
overall performance of the carrier varies throughout literature due to the heterogeneity of 
nanoparticle systems and disease models investigated.20 In an effort to compare how 
nanoparticle parameters impact tumor accumulation and penetration, we have compiled data 
(Table 1) from the literature spanning multiple particle matrices, as well as particle sizes and 
shapes and tumor models. Upon the basis of this compilation, nanoparticles with enhanced 
circulation half-lives resulted in higher tumor accumulation, smaller nanoparticles displayed 
enhanced tumor extravasation/penetration, and tumor models play a major role in both tumor 
accumulation and extravasation of nanoparticles.8–11,16–19 These results illustrate the 
complicated nature of particle tumor deposition, highlighting how imperative it is to 
exhaustively evaluate not only the particle, but also the tumor models, such that tumor 
characteristics that favor nanoparticle accumulation can be identified to help establish 
guidelines for determining which cancers/patients could benefit from nanoparticle 
therapeutics.
To this aim, we investigated tumor accumulation and penetration as a function of 
nanoparticle size, cancer cell type, and tumor location, while also characterizing tumors for 
EPR mediating factors such as microvessel density, vascular permeability, lymphatics, 
stromal content, and tumor associated macrophages. Utilizing PRINT, three distinct 
nanoparticle sizes were manufactured: 55 nm × 55 nm × 60 nm (55 × 60 nm), 80 nm × 80 
nm × 180 nm (80 × 180 nm), and 80 nm × 80 nm × 320 nm (80 × 320 nm). All particles 
were densely coated with PEG postfabrication. In vitro, there was no discernible difference 
in cellular interaction between the nanoparticle types. In vivo, biodistribution and blood 
pharmacokinetic profiles were statistically similar among all three NPs in nude mice. 
Administration of PRINT NPs into four different subcutaneous murine tumor models 
showed dramatically different tumor accumulation between the different tumor models with 
evident particle size dependence. Immuno-histochemistry (IHC) staining revealed distinct 
differences in tumor microvessel densities that seemed to correspond with overall tumor 
deposition. Finally, three orthotopic, metastatic tumor models (344SQ, A549, and SKOV3) 
were evaluated revealing equivalent if not higher accumulation in metastatic lesions over 
primary tumors. Overall, tumor accumulation was observed to vary dramatically with 
particle size, cancer cell line, and tumor location.
Nanoparticles were fabricated on a continuous roll-to-roll lab line utilizing PRINT 
technology. Particle composition was comprised of PEG acrylate monomers and an amine 
terminated monomer (aminoethyl methacrylate) allowing for facile surface modifications 
through NHS (N-hydroxysuccinimide) chemistry. Particles of three different sizes/shapes 
were fabricated: 55 × 60, 80 × 180, and 80 × 320 nm (Figure 1a). It is well-known that 
Perry et al. Page 3
Nano Lett. Author manuscript; available in PMC 2017 November 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
surface PEG density can play an important role in determining particle fate in vivo.21 To this 
end, following reported protocols, particle surface amines were reacted with methoxy-
terminated PEG-succinimidyl carboxy methyl ester, surface PEG densities were calculated 
across all particle sizes/shapes and were held constant at ~0.09 PEG/nm2 (details available 
in Supporting Information, Figure S1), and particle PEGylation was followed by acetylation 
of the remaining amines.21 After surface PEGylation and acetylation, particles were 
negatively charged and remained fairly monodisperse as shown by the negative zeta 
potential and narrow polydispersity index (PdI) values shown in Table 2. Because the 
hydrogel PRINT particles are rod-shaped and swell in water, the reported size determined by 
dynamic light scattering is a qualitative assessment of the particles and represents the 
diameter of a sphere with the same translational diffusion speed as the nonspherical 
particles.
Extending circulation time of nanobased drug delivery systems upon intravenous (iv) 
administration is an important factor facilitating accumulation in cancerous tissue. By 
improving blood retention, particulate drug systems have a greater probability of permeating 
into the porous and hypervascularized neoplastic tissue. In previous accounts (Table 1), 
nanoparticle size has been closely attributed to unique blood pharmacokinetic profiles with 
smaller particulates extending blood retention.16–19 In addition, particle size is widely noted 
as the most dominant parameter improving solid tumor accumulation and penetration (Table 
1).8,11,16–19 The intertwined relationship of nanoparticle size, blood PK, and tumor 
accumulation complicates the ability to determine which factors lead to improved 
nanoparticle tumor delivery. Because of this complicated relationship, we conducted blood 
pharmacokinetic studies with fluorescently labeled, PEGylated PRINT NPs of three distinct 
sizes: 80 × 320, 80 × 180, and 55 × 60 nm in nontumor bearing Foxn1nu mice (dosed with 
60 mg/kg of each NP type). Unlike previous literature results listed in Table 1,9,16–19,22 
blood pharmacokinetic profiles of the three NP types displayed no statistically significant 
differences in PK behavior (Figure 1b). Key pharmacokinetic parameters for different NP 
sizes such as circulation half-life (t1/2 β), volume of distribution (Vd), and area-under-curve 
(AUC) all fell within statistically similar values of approximately 13–20 h, ~1.3 mL, and 15 
mg/mL·h, respectively (Table 2). These results indicate that any differences in tumor 
accumulation can be attributed to particle size and not differences in pharmacokinetic 
behavior. Furthermore, biodistribution analysis was conducted at 24 h post NP injection. 
Organs were resected, weighed, and analyzed for fluorescence. Nanoparticle organ 
accumulation is displayed as percent recovered fluorescence per gram of tissue, which was 
determined by dividing the collected fluorescence from each tissue by the total sum 
fluorescence of all excised tissues for each individual mouse. The results revealed similar 
deposition between primary tissues associated with nanoparticle clearance for all NP types 
(Figure 1c) with slight variations observed within the lung and kidneys.
While blood pharmacokinetic profile and biodistribution of the three different sized PRINT 
hydrogels were similar, it was of interest to validate in vitro behavior. In previous accounts, 
cellular interactions with nanoparticles were heavily influenced by particle shape and size.23 
It was reported that high aspect ratio nanoparticles were internalized at a faster rate in HeLa 
cells.23 We therefore wanted to assess target (cancer) and nontarget (macrophage) cell 
interactions with the three particle sizes/shapes. We observed no trend across the cancer cell 
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lines, and after a 24 h incubation period with NPs all nanoparticle sizes were poorly 
associated with the cancer cell lines of interest and displayed low cellular uptake (Figure 
S2). As expected, the phagocytic uptake by alveolar murine macrophage (MH-S) of all three 
nanoparticles types was approximately 20–30% association after 24 h which is similar to our 
previous report for PEGylated 80 × 320 nm particles.21
In an effort to validate the impact of various PRINT NPs toward solid tumor delivery, we 
analyzed accumulation in several murine subcutaneous flank tumor models. While flank 
tumor models are hardly predictive for the human diseased condition, they are frequently 
used in nanoparticle drug delivery literature as a primary screen due to ease of use and rapid 
growth. The aims of these studies were to determine how NP accumulation varied across 
different flank tumor models and how these findings compared to orthotopic cancer models, 
which more closely resemble the morphology, microenvironment, and metastatic patterns of 
human cancer.24,25
Foxn1nu mice were injected subcutaneously in the right flank with either A549 (human 
nonsmall cell lung cancer cells), A431 (human epidermoid cancer cells), SKOV3 (human 
ovarian cancer cells), or 344SQ (murine nonsmall cell lung cancer cells). It is documented 
that tumor size can also influence EPR, so throughout these experiments we held tumor size 
constant at approximately 100 mm3.5,6 When flank tumors reached 100 mm3, mice were 
injected (tail vein) with 60 mg/kg of 80 × 320, 80 × 180, or 55 × 60 nm fluorescently labeled 
PRINT particles. Particle biodistribution was assessed 24 h post NP injections via organ 
resection and fluorescent imaging. Upon fluorescence analysis, it was evident that both 
nanoparticle size and xenograft model had dramatic effects on overall accumulation in the 
solid flank tumors (Figure 2A). The tumor exposure of the 55 × 60 nm particle was greater 
than all other particle types in the A431, SKOV3, and 344SQ flank tumor models. 
Interestingly, in the A549 flank tumor model, the 55 × 60 and 80 × 180 nm particles tumor 
exposure were similar and greater than 80 × 320 nm particle. In most cases, a positive 
correlation existed between reductions in NP size and flank tumor accumulation; however, it 
is currently unknown whether pore cutoff size in the tumor vasculature is the main driver of 
this observation. At 24 h post NP injections, three of the four flank models (SKOV3, A431, 
and A549) had tumor accumulation ranging from approximately 3–15% recovered 
fluorescent dose, depending on the NP type, yet the 344SQ tumor model yielded 
significantly increased accumulation, ranging between ~15–38% recovered fluorescent dose. 
Biodistribution to organs in flank tumor-bearing mice displayed similar distributions 
throughout the four models with slight variations in spleen and liver delivery (Figure S3). It 
is reasonable to assume that alterations in biodistribution between tumor models can in part 
be attributed to differences in the tumor depot, as biodistribution in nontumor bearing mice 
was statistically similar.
Upon resection of flank tumors (from mice not treated with nanoparticles), differences in 
tumor appearance and H&E stains were noted (Figures S4 and S5). Immunohistochemistry 
staining was conducted to determine variance in biomarkers for EPR mediating factors such 
as blood vessels (CD31 marker), stroma (Collagen IV marker), tumor associated 
macrophages (F4/80 marker), vasculature permeability (VEGF marker), and lymphatics 
(Lyve-1 marker). Immunofluorescence imaging of sectioned tumors (from mice treated with 
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nanoparticles) was used to further evaluate the distribution of fluorescently labeled particles 
throughout the tumor relative to blood vessels (CD31 marker).
Quantitative analysis of microvessel densities revealed that the 344SQ tumors had the 
highest microvessel density, followed by SKOV3, A431, and A549 tumors (Figure 2b). The 
microvessel density correlated well with overall flank tumor deposition of NPs. This is in 
agreement with the report that tumors with high angiogenic activity are expected to have 
more permeable blood vessels, resulting in higher intratumoral deposition of nanocarriers.4
Furthermore, this is partially consistent with the observation that faster tumor growth rate 
resulted in higher particle accumulation.4 The 344SQ flank tumors reached 100 mm3 within 
1.5 weeks, followed by A431 (3.5 weeks), SKOV3 (7 weeks), and A549 (8 weeks). Other 
histological differences were observed for the expression of collagen and TAMS across the 
tumor models. Both lung cancer models (A549 and 344SQ) exhibited the highest expression 
of collagen and TAMs, followed by the SKOV3 and A431 models (Figure 2c). We observed 
no difference across tumor models for the level of permeability (VEGF) or lymphatics 
(Lyve-1) (Figure 2c).
Immunofluorescence imaging of the sectioned A549 tissue was conducted in an effort to 
visualize particle size-dependent intratumoral distribution relative to the location of blood 
vessels (Figure 3a). Interestingly, based on fluorescence imaging of the entire flank tumor, 
this model exhibited statistically similar recovered fluorescence in the tumor for both the 55 
× 60 and 80 × 180 nm particles (Figure 2a). However, evaluation of the intratumoral 
microdistribution of the particles (Figure 3a) revealed that the 80 × 180 nm particles behaved 
more like the 80 × 320 nm particles with particle signal (red) concentrated close to blood 
vessels (green). Whereas high particle signal (red) on the blood vessel periphery as well as 
diffuse signal within the tumor mass was observed for the 55 × 60 nm particles (Figure 3a). 
Furthermore, we compared 55 × 60 nm particle distribution throughout the four flank tumor 
models (Figure 3b). Throughout literature there is a consensus that elevated tumor stromal 
content represents a barrier to particle penetration.8,12,26–28 In line with the literature 
reports, we observed aggregates of particle fluorescence around the blood vessels and 
limited diffuse particle signal throughout the tumor tissue in both the A549 and 344SQ 
models (Figure 3b), which were characterized by having high collagen, a marker for stromal 
content (Figure 2c). The SKOV3 and A431 models had less stromal content, and as expected 
we saw more diffuse signal throughout the tissue (Figure 3b).
Assessment of drug or drug carrier performance in clinically relevant animal models is 
imperative to ascertain potential successes in the clinic. While there are obvious limitations 
translating discoveries from mice to humans, there are certain mouse models that better 
reflect human cancer pathology.29 To this end we assessed particle (55 × 60 nm) deposition 
within three different metastatic orthotopic mouse models, two human xenograft models in 
immune compromised nude mice (A549 and SKOV3), and one syngeneic model (344SQ) in 
immune competent SvJ mice.
For the two orthotopic lung cancer models (344SQ and A549), tumor cells were injected 
directly into the left mouse lung; the orthotopic ovarian cancer model (SKOV3) was 
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developed by injecting tumor cells into the peritoneal cavity of the mice. In the lung models, 
the formation of primary tumors at the injection site was observed, along with significant 
metastases. The A549 model was more metastatic and spread not only to the lymph nodes 
but also to the pleural cavity and chest wall, whereas only lymph node metastases were 
observed in the 344SQ model (Figure 4). Fluorescent images display in a compelling fashion 
dramatic particle accumulation in the diseased sites as compared to the surrounding healthy 
lung tissue (Figure 4). The orthotopic ovarian model resulted in a large solid tumor mass in 
the intraperitoneal cavity and liver metastases (Figure S6). Again, particle distribution was 
observed at different extents in each orthotopic model with the 344SQ tumors maintaining 
the highest recovered fluorescent dose at 24 h post NP injection (Figure 5a). Furthermore, 
particle distribution in the three orthotopic models did not necessarily reflect what was 
previously observed in the flank xenograft models. Most notably, the drastic variance in the 
A549 cell-line, where we observed a 5-fold increase in recovered fluorescence in the 
orthotopic model (34 ± 13%) over the flank model (7 ± 2%) (Figure 5a). Interestingly, 
particles accumulated to the same extent in the A549 primary orthotopic tumors (8 ± 2% 
recovered fluorescent dose) as they did in the flank tumors (7 ± 2% recovered fluorescent 
dose) (Figure 5b), however, the summation of particle accumulation in the metastatic tumors 
(lymph node, chest wall, and pleural cavity) resulted in approximately 30% recovered 
fluorescence, boosting the overall particle accumulation in the orthotopic model to 
approximately 40% recovered fluorescent dose (Figure 5a). One possible explanation for 
this change in accumulation is the size of the tumors, as higher particle accumulation has 
been previously documented in smaller tumors (less than 100 mg).30 In this orthotopic A549 
tumor model, the tumors that formed within the pleural cavity, chest wall, and lymph nodes 
were small with the total mass of the tumors approximating 60, 70, and 20 mg, respectively. 
The increased number of tumors also resulted in more potential nanoparticle “sinks” and 
consequently higher tumor accumulation overall. Another possible explanation could be the 
change in vascular perfusion and blood vessel functionality as Graves and colleges recently 
documented that the vasculature formed by A549 tumors in the lung was more functional 
than those formed by the same tumor cells grown subcutaneously.31 These same arguments 
can be used for the orthotopic 344SQ model, whereas we observed 37 ± 8% recovered 
fluorescent dose in the flank model (Figure 5a) and similar accumulation in the primary lung 
tumors (23 ± 7% recovered fluorescent dose) (Figure 5c). However, due to the added “sink” 
of the lymphatic metastasis (resulting in 31 ± 13% recovered fluorescent dose), the overall 
particle accumulation in the orthotopic model was boosted to approximately 50% recovered 
fluorescent dose (Figure 5a). There was no significant difference between tumor 
accumulation in the flank and orthotopic SKOV3 tumors. This could be due to the overall 
size and number of tumors, as the intraperitoneal tumor formed a large mass rather than a 
cluster of small tumors (Figure S6). For this case, we observed approximately 7 ± 3% 
recovered fluorescent dose in the solid IP tumors with an additional 11 ± 4% recovered dose 
from the liver metastasis, elevating the overall recovered fluorescent dose in the orthotopic 
model to approximately 20% (Figure 5a,d). Complete organ biodistribution in each 
orthotopic model can be found in Supporting Information (Figure S7).
In summary, our study provides new insights into how nanoparticle tumor delivery is highly 
dependent on nanoparticle size, tumor model, and tumor location, emphasizing the 
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heterogeneity of the EPR effect across tumor models and tumor locations. We utilized three 
distinctly sized PRINT hydrogels (80 × 320, 80 × 180, and 55 × 60 nm), yet having similar 
blood pharmacokinetic behaviors, to investigate the impact of particle size on tumor 
accumulation and penetration in four murine subcutaneous flank tumor models and three 
orthotopic tumor models. We observed vastly different accumulation among the different 
particle types and tumor models. In agreement with literature reports, the smallest particle 
accumulated to the highest extent.8,17,19 Nanoparticle accumulation in tumors correlated 
with tumor microvessel density, while NP penetration within tumors was mainly influenced 
by the stromal content in each tumor model. Perhaps of most importance was the 
investigation of metastatic, orthotopic tumor models, revealing significant accumulation of 
55 × 60 nm particles in both primary and metastatic sites. For all metastatic orthotopic 
models we observed equal if not higher nanoparticle accumulation in the metastatic lesions 
versus the primary tumors. Overall tumor accumulation in the orthotopic lung cancer models 
was higher than the flank lung cancer models, further establishing that flank lung cancer 
models are not predictive for tumors grown in the lung. However, tumor accumulation was 
constant for both orthotopic and flank ovarian cancer models. These results demonstrate the 
variability in the EPR effect as a function of both tumor model and location. While other 
researchers have compared tumor accumulation as a function of nanoparticle size, or across 
tumor models, to our knowledge we are the first to evaluate the effect of nanoparticle size, 
tumor model, and tumor location. As the EPR effect has become a controversial issue in 
cancer NP drug development, it is important to understand and determine the tumor 
characteristics that lead to enhanced NP accumulation, and based upon Miller’s recent 
findings NP tumor accumulation can be used predict efficacy of therapeutic nanoparticles.32 
To this end, we observed that our smallest nanoparticle had the highest tumor accumulation, 
however it is yet to be determined how this will translate when a therapeutic cargo is 
incorporated, as the smaller particles incorporate less payload. Furthermore, we have 
determined that tumor location, blood vessel density, and stromal content are of the major 
characteristics that impact nanoparticle tumor accumulation and penetration, and potentially 
the efficacy of nanoparticle agents. For example, the 344SQ tumor model had the highest 
microvessel density and nanoparticle tumor accumulation but also had a high level of 
collagen, effectively sequestering the particles close to the blood vessels and preventing 
particle penetration into the tumor. Investigations are ongoing to determine if this finding 
will limit the NPs therapeutic effect. We also observed different levels of TAMS across 
tumor models; although these levels did not directly correlate with either nanoparticle tumor 
accumulation or penetration, there is literature to suggest that they will play a large role in 
nanoparticle drug delivery,13 while also giving us secondary targets for 
immunomodulation.33,34 As many in the scientific community have noted, determining 
factors that improve nanoparticle tumor accumulation are only “a piece of a complex 
puzzle”.35,36 Future investigations will continue to instruct the scientific community on the 
role of particle size, drug loading/release, and tumor physiology in achieving therapeutic 
efficacy. These types of studies, combined with patient biopsy-based information, could lead 
to the identification of additional parameters that will allow for the preselection of patients 
that would likely benefit from nanomedicine therapy, therefore improving the performance 
of nanomedicines in the clinic.
Perry et al. Page 8
Nano Lett. Author manuscript; available in PMC 2017 November 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank Dr. Ashish Pandya for the synthesis of HP4A, and the University of North Carolina Animal Studies Core, 
specifically Charlene Santos and Mark Ross for their assistance with all animal studies. Additionally, we thank 
Liquidia Technologies for providing PRINT molds used in the fabrication of our nanoparticles, and the 
Translational Pathology Lab, specifically Nana Feinberg and Yonjuan Xia for their help with 
immunohistochemistry and immunofluorescence samples.
Funding
This work has been supported by the University Cancer Research Fund and the Carolina Center for Cancer 
Nanotechnology Excellence (U54CA151652 and U54CA198999).
ABBREVIATIONS
PRINT particle replication in nonwetting templates
NP nanoparticle
EPR enhanced permeation and retention
PEG polyethylene glycol
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Figure 1. 
Particle characterization through scanning electron microscopy (scale bar represents 1 μm) 
(a) in vivo blood concentration versus time profiles (b) and biodistribution of 55 × 60, 80 × 
180, and 80 × 320 nm PRINT particles in healthy mice, 24 h postinjection of 60 mg/kg (c), 
error bars represent standard deviation (N = 4). The percentage of recovered fluorescence 
per gram of tissue for each organ was calculated by dividing collected fluorescence from 
each tissue by the total sum fluorescence of all excised tissues for each individual mouse.
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Figure 2. 
Nanoparticle accumulation and immunohistochemistry analysis of flank tumors. Flank 
tumor accumulation of PRINT particles of various sizes and shapes was evaluated at 24 h 
postinjection at 60 mg/kg, data displayed as percent recovered fluorescence per gram of 
tissue (a). Vascularization of the cancerous tissue was identified with a CD-31 marker, and 
microvessel density was determined as the total number of blood vessels divided by tumor 
area (b). H-scores for each marker per tumor model were also quantitated (c) lymphatic 
vessels identified with Lyve1, tumor-associated macrophage identified with F4/80, collagen 
identified with Collagen IV, and vascular endothelial growth factor identified with VEGF. 
Error bars represent standard devation (N = 4), analyzed by one-way ANOVA followed by 
Tukey’s multiple comparison test; **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Figure 3. 
Tumor microdistribution of fluorescently labeled particles of varying sizes in A549 tumors 
(a) and 55 × 60 nm PRINT particles in various flank tumors (b). Particles were labeled with 
dylight 680 (red), blood vessels were marked with fluorescently labeled CD31 antibody 
(green). Scale bars are all 100 μm.
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Figure 4. 
Photograph and fluorescence images of orthotopic 344SQ (left two) and A549 (right two) 
tumors treated with fluorescently labeled 55 × 60 nm PRINT particles, indicating 
preferential accumulation of particles in diseased tissue. White triangles indicate primary 
tumors, and blue triangles indicate metastasis.
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Figure 5. 
IVIS analysis of fluorescently labeled 55 × 60 nm PRINT particles (24 h post injection) in 
primary and metastatic disease sites throughout the three orthotopic mouse models. (a) 
Comparison of orthotopic and flank tumor accumulation, (b) accumulation in primary and 
metastatic A549 tumors, (c) accumulation in primary and metastatic 344SQ tumors, (d) 
accumulation in primary and metastatic SKOV3. Error bars represent standard deviation (N 
= 4), analyzed by one-way ANOVA followed by Tukey’s multiple comparison test; *P < 
0.05, **P < 0.01.
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Table 2
Particle Characterization by Dynamic Light Scattering and Blood Pharmacokinetics
55 × 60 nm 80 × 180 nm 80 × 320 nm
Z-avg (nm) 126 ± 4     184 ± 4     257 ± 5     
PdI 0.09 ± 0.01 0.07 ± 0.01 0.01 ± 0.01
ZP (mV) −19 ± 1     −20 ± 1     −23 ± 1     
t1/2 α (h) 4.0 ± 4.4  7.7 ± 3.1  4.5 ± 1.9  
t1/2 β (h) 12.8 ± 1.4  14.7 ± 2.9  20.3 ± 7.3  
Vd (mL) 1.4 ± 0.1  1.3 ± 0.1  1.3 ± 0.2  
CL (mL/h) 0.08 ± 0.01 0.09 ± 0.02 0.08 ± 0.01
AUC0−t (mg/mL·h) 15.4 ± 1.9  14.3 ± 3.0  14.6 ± 1.3  
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